“Clinicians caring for infants requiring gastroschisis repair now have a human milk-based nutritional option to support healthy growth and recovery,” said Melinda Elliott, MD, FAAP, practicing neonatologist and chief medical officer at Prolacta. “Surgifort fortifier extends the benefits of Prolacta’s Exclusive Human Milk Diet beyond premature infants to this fragile surgical population.”

About Prolacta Bioscience
Prolacta Bioscience® is a global life sciences company dedicated to Advancing the Science of Human Milk® to improve health outcomes for critically ill and premature babies. More than 100,000 extremely premature infants worldwide5 have benefited from Prolacta’s human milk-based products, which have been evaluated in more than 30 peer-reviewed clinical studies. Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta maintains the industry’s strictest quality and safety standards, with over 20 validated tests for screening and testing human milk. Prolacta’s manufacturing process uses vat pasteurization to ensure pathogen inactivation while protecting nutritional composition and bioactivity. Learn more at page.prolacta.com/surgifort, on X, Instagram, Facebook, and LinkedIn.

Media Contact:
Loren Kosmont
[email protected]
310-721-9444

The post FDA Approves First Human Milk-Based Fortifier for Term Infants to Support Growth and Recovery Following Surgery for Gastroschisis first appeared on EW Healthcare Partners.

New York, NY – EW Healthcare Partners, a trans-Atlantic healthcare private equity firm, today announced that it has appointed Dr. Petri Vainio as Executive Chairman, Dr. Evis Hursever as CEO, Scott Barry as COO, and Marty Sutter as Founding Partner.

Petri Vainio, M.D., Ph.D., has served as Chairman of the firm’s Executive Committee since 2015 and has helped to raise three growth equity funds and one continuation fund, representing over $2 billion of capital. Dr. Vainio will chair the firm’s Investment Committee.

Evis Hursever, Ph.D., joined EW in 2011 and currently serves as Managing Director as well as a member of the Investment Committee. Since joining EW, Dr. Hursever has been instrumental in building the firm’s investment practice, playing a key role in several successful investments, including the sale of EUSA Pharma to Recordati for $825M and the sale of Cognate BioServices to Charles River Laboratories for $875M. She is currently leading the firm’s investments in ABL, Boiron, and Germfree in the US, and Grundium and Majorelle in Europe. In her new role, Dr. Hursever will lead EW’s investment practice and team.

Scott Barry joined EW in 2006 and currently serves as a Managing Director as well as a member of the Investment Committee. Scott has taken on increasing responsibility over the last few years in EW’s finance, legal, regulatory, compliance and administrative activities and will now formally lead these functions.

Marty Sutter is a Co-Founder of EW and currently serves as a Managing Director as well as a member of the Investment Committee. He will focus his time on originating and leading successful investments, including his current role in leading the firm’s investments in Bioventus, MiMedx and Prolacta.

Petri Vainio commented: “Evis has been a key leader of EW’s investment practice for several years and has led many of the firm’s most successful growth buy-out investments, both in Europe and in the US. Evis’ promotion is a well-deserved recognition of the value she has created for the firm, our portfolio companies, and our investors. I look forward to continuing to work closely together with Evis and Scott to build EW into one of the leading trans-Atlantic healthcare-focused private equity firms.”

“I am excited to lead the next chapter in the evolution of EW,” said Evis Hursever. “We have the great privilege of investing in and owning numerous fast-growing companies that make a difference in thousands of patients’ lives. I look forward to leading the EW investment team and partnering with the owners and managers of the next generation of companies transforming healthcare.”

About EW Healthcare Partners

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages, and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London, and Houston. For more information, see https://www.ewhealthcare.com

The post EW Healthcare Partners Announces Leadership Evolution first appeared on EW Healthcare Partners.

“We founded Ascend with a vision to quilt together the best operators and technologies within the advanced manufacturing field. The complementary services at ABL and Ascend will further strengthen our service offering to customers,” Fred Cohen, Chairman of Ascend and Founding investor at Monograph Capital offered. “We look forward to working with our new colleagues at the Rockville facility and our partners at EW.”

The addition of the ABL Rockville team and facility aligns more than three decades of development and manufacturing experience with additional virus modalities and GMP capacity for adeno-associated virus (AAV) production. The merger also expands fill/finish capacity in the US making the combined group one of the few suppliers with a comprehensive R&D to commercial offering in the market.

“This alignment deepens our already exceptional AAV expertise with the new team members from ABL. Not only are we expanding our GMP capacity, but this merger allows the team to offer customers an even more sophisticated gene-to-GMP experience,” Mike Stella, CEO of Ascend commented. “We are incredibly pleased to welcome EW Healthcare Partners as a new investor in Ascend and ABL to the Ascend family. The strong support from our existing investors has been instrumental in completing this transaction and will be crucial as we continue to drive growth in the new company.”

“We have known Ascend and followed its progress in creating effective and high-quality gene therapies, and have been impressed with how the management team, which we also backed at Cognate BioServices, has expanded the business. We are excited about merging ABL with Ascend to create a scalable CDMO that will serve as a global platform for the manufacturing of advanced therapies. We have considerable experience and expertise in this space and the combined company’s strategic plans are very well aligned with our long-term vision. We look forward to working with the Ascend and ABL teams to further growth”, concluded Evis Hursever, Ph.D., Managing Director of EW Healthcare Partners.

The merger complements an active year for Ascend, including operational investments and progress in the US and Europe. In Q2 of 2024, GMP capacity was purchased in Alachua, Florida that is undergoing a capacity expansion, including new fill/finish capabilities. In Munich, Germany, GMP quality control (QC) testing, analytical, and process development capacity are close to launch, and that facility is also in expansion.

The ABL brand and website will stay intact through the initial transaction. To stay up to date with our teams, find ABL Bio at https://ablinc.com/ or find Ascend at https://www.ascend-adv.com. Follow co-branded updates on LinkedIn or reach out at [email protected].

About Ascend

Ascend Advanced Therapies (Ascend) is a gene-to-GMP CDMO specializing in high-quality, cost-effective advanced therapy development and manufacturing. Established in clinical AAV innovation since 1991, Ascend now offers expanded commercial facilities and a versatile platform that supports multiple modalities. Our collaborative CMC approach guides clients from clinic to commercialization, aiming to balance yield and quality in life-saving therapies. The investment foundation for the company includes Abingworth, Anjimoto, Cathay Health, Deerfield, Digitalis Ventures, DCVC Bio, 4BIO Capital, Monograph, and Petrichor. Learn more at www.ascend-adv.com.

About EW Healthcare Partners

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages, and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London, and Houston. For more information, see https://ewhealthcare.com/

About ABL

Advanced BioScience Laboratories (ABL) is a contract development and manufacturing organization (CDMO) dedicated to advancing therapeutics, vaccines, and other biological products. With over 60 years of experience working with diverse organizations including industry, government, and academic entities, ABL provides manufacturing capabilities for the development and production of virus-based oncolytic therapies, gene therapies and viral vaccines. GMP facilities are in Rockville, MD with services including bulk drug substance, live virus fill/finish, process, and assay development for clinical products.

For media inquiries, please contact:

Media Contact Information: [email protected]

The post Ascend Advanced Therapies Partners with EW Healthcare Partners to Expand United States Capacity and Capabilities first appeared on EW Healthcare Partners.

MIAMI,FL—BioTissue, a leader in regenerative healing, using cryopreserved human birth tissue products for ocular surface disease, chronic wounds, and musculoskeletal conditions, has ranked #14 on Great Place To Work® and Fortune Magazine’s 2024 Fortune Best Workplaces in BioPharma™ List. This prestigious recognition, awarded based on employee feedback gathered through independent evaluations, highlights companies excelling in workplace culture. As the global benchmark for such recognition, Great Place to Work® sets the standard for identifying organizations where employees thrive.

“We are thrilled to be recognized for our commitment to creating a positive and supportive culture,” said BioTissue CEO Ted Davis. “Over the past year, BioTissue has continued to evolve, yet our dedication to providing the resources, support, and opportunities for our employees to grow has remained constant. This esteemed recognition reaffirms our ability to adapt while staying focused on the well-being and success of our team.”

BioTissue employees have the opportunity to make a meaningful impact in people’s lives while being on the cutting edge of biotechnology advancements. Their Trust Index™ Employee Survey results reflect the pride and fulfillment they experience in being part of such a dynamic and innovative workplace. An incredible 91% of BioTissue employees reported the company as a great place to work compared to 57% of employees at a typical US-based company1. In open-ended comments, words like “people,” “culture,” and “team” were most frequently mentioned when employees were asked what makes the company special. Additionally, 94% of employees expressed pride in telling others they work at BioTissue.

Being named both a Great Place to Work Certified™ company and a Fortune Best Workplace in BioPharma™ offers BioTissue research-backed validation for cultivating an exceptional employee experience. This recognition supports the foundation for achieving our vision of unlocking the full potential of regenerative therapy.

For career opportunities, visit https://biotissue.com/about-us/careers/.

# # #

Source: Great Place To Work® 2021 Global Employee Engagement Study

About BioTissue Holdings Inc.

BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of Cryopreserved Amniotic Membrane (CAM) products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple Investigational New Drug (IND) clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 900,000 human implants with its products and published over 400 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at https://biotissue.com.

Media Contact

Laura DiCaprio

McDougall Communications for BioTissue

[email protected] or (585) 434-2153

The post BioTissue Earns Top Ranking on Great Place to Work® and 2024 Fortune Best Workplaces in BioPharma™ List first appeared on EW Healthcare Partners.

Beyond his role as a Senior Advisor with EW Healthcare Partners, Olivier was a distinguished and accomplished executive in the pharmaceutical and medical device industries. His career culminated in roles as President of Abbott’s pharmaceutical division, and Chief Executive Officer with both Pierre Fabre, one of the largest pharmaceutical companies in France, and Smith & Nephew, one of the largest global medical device companies. Olivier also served as a board member of several leading healthcare companies worldwide including Takeda, one of the largest pharmaceutical companies in Japan; Reckitt Benckiser, one of the largest global consumer healthcare companies; and Virbac, one of the largest veterinary medicine companies in the world.

Olivier was a valued member of our partnership, who contributed significantly to our investment practice, and played an important role in our recent investments in Laboratoires Majorelle and Boiron. He was a much loved and admired colleague and partner and left a lasting legacy on our London office.

In addition to his exceptional professional acumen, Olivier was a man of wisdom and insight. His gentle and caring personality endeared him to all, both colleagues and friends. Olivier’s passing is a tremendous loss not only to the partnership but also to the pharmaceutical and medical device industries. Olivier’s absence will be deeply felt by all who knew him, but his remarkable spirit and legacy will continue to inspire us.

The post In Memoriam: Olivier Bohuon first appeared on EW Healthcare Partners.

By combining Germfree’s expertise in designing, manufacturing, and maintaining advanced manufacturing facility environments with Orgenesis’ cutting-edge processes and analytical development capabilities, the partnership seeks to significantly reduce the production costs of cell and gene therapy products. The ultimate goal is to enable broader adoption of life-saving treatments.

Vered Caplan, CEO of Orgenesis, stated, “Under the agreement, Orgenesis and Germfree will join forces to co-market Orgenesis’ decentralized Octomera service platform, and its Octomera Mobile Processing Units and Labs (OMPULs™) globally. The partnership marks a significant milestone in the bio- manufacturing industry, as the industry begins to pivot to the paradigm-shifting distributed processing of cell and gene therapies (CGTs). Germfree will be marketing, manufacturing, and servicing OMPULs as part of its modular cleanroom fleet, enabling Orgenesis to focus on its therapeutic pipeline with an emphasis on immuno-oncology. We are delighted to work with Germfree to meet the growing demand for our platform.”

Victor Miller, CFO of Orgenesis, remarked on the financial and strategic significance of the partnership, stating, “This collaboration significantly supports Orgenesis’ infrastructure growth requirements while immediately providing a commercial footprint that will significantly impact market expansion opportunities for the partnership.”

Carol Houts, Chief Strategy Officer at Germfree, highlighted the innovative potential of the partnership, “Our collaboration with Orgenesis transcends traditional boundaries, setting a new standard for the industry. By harnessing the power of digital workflows and advanced quality management systems, we believe that we are not just streamlining production but revolutionizing it. This partnership is expected to foster innovation, particularly in how we approach and execute cell and gene therapy manufacturing. Moreover, our joint efforts with regulatory authorities worldwide are expected to ensure that our advancements not only meet, but exceed, global standards. The synergy between Germfree and Orgenesis paves the way for a future where regulatory collaboration and digital
innovation ensure that life-saving therapies are developed and delivered with high efficiency and quality.”

Kevin Kyle, CEO of Germfree, shared his insights on the collaboration, “Our strategic partnership with Orgenesis is a cornerstone in the continuation of our mission to advance healthcare solutions globally. By integrating Germfree’s modular cleanroom technology with Orgenesis’ innovative cell and gene therapy programs, we are seeing a new benchmark for efficiency and accessibility in the treatment of life-threatening conditions. This collaboration is not just about enhancing production capabilities; it’s about creating a paradigm shift in how cell therapies are developed, produced, and delivered to those in dire need. Together, we are building the foundation for a future where advanced medical treatments are no longer a privilege, but a right, accessible to everyone, everywhere.”

For more information about Germfree and Orgenesis and their strategic partnership, please visit www.germfree.com and www.orgenesis.com.

About Germfree

Germfree is a global leader in the design, manufacture, and maintenance of modular cleanroom environments. With decades of global expertise in serving the biopharmaceutical industry, Germfree specializes in providing advanced solutions that enhance the safety, efficiency, and sustainability of critical healthcare manufacturing processes. Germfree is continuing to invest in cleanroom design and manufacturing solutions and is committed to providing innovative solutions, with the goal of improving patient access to critical medicines. Germfree is backed by the healthcare growth equity investor, EW Healthcare Partners. www.germfree.com

About Orgenesis

Orgenesis is a global biotech company that has been committed to unlocking the potential of cell and gene therapies (CGTs) since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020. This new model allows Orgenesis to bring academia, hospitals, and industry together to make these essential therapies a reality sooner rather than later. Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger number of patients more cost effectively and with better outcomes through great science and decentralized production.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our decentralized cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our decentralized cell therapy processing, our ability to further our CGT development projects, either directly or through our JV partner agreements,
and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us, our ability to remain listed on Nasdaq and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor relations contact for Orgenesis:

Crescendo Communications, LLC
Tel: 212-671-1021
Email: [email protected]

Communications contact for Orgenesis:

IB Communications
Michelle Boxall

Media Contact for Germfree:

Lauren Blum, Content Marketing Manager at Germfree
+1 386-265-4300
[email protected]

The post Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility first appeared on EW Healthcare Partners.

“We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of Directors.  Their counsel will guide strategic alternatives, aid Germfree in capitalizing on opportunities, and navigate future challenges. Leveraging their collective expertise, the Board will play a pivotal role in driving sustainable growth and ensuring long-term success. Germfree’s story is one of relentless innovation, unwavering commitment to quality, and profound impact on global health. We remain committed to advancing innovation and maintaining our position as a leader in critical environment equipment, cleanrooms, and laboratories. Our Board will help Germfree to capitalize on emerging trends and technological advancements, particularly in the rapidly evolving fields of cell and gene therapy,” said Kevin Kyle, CEO at Germfree.

Dorothy Puhy brings considerable experience to the Germfree Board and is well recognized for her financial expertise. She dedicated 25 years to the Dana Farber Cancer Institute, culminating in her role as Executive Vice President and Chief Operating Officer. Prior to that, she was Chief Financial Officer and held various financial positions at the Tufts – New England Medical Center Hospitals. Dorothy served as a Lead Director at Abiomed for c. 20 years, until the successful acquisition of the company by JNJ. As a Lead Director of Abiomed, Dorothy worked closely with the management team and other Board members to set strategic goals and overall direction. In addition to Abiomed, Dorothy served on the boards of BCBS, Azenta and Reebok. She was on the adjunct faculty at Harvard School of Public Health for many years.

Karen Flynn brings more than three decades of commercial and operations experience to the board of Germfree. Most recently, she served as Interim President of BioModalities at Catalent. Preceding this role, Karen held positions as Chief Commercial Officer and President of Biologics at Catalent. Prior to her tenure at Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services, also assuming the role of President of its Pharmaceutical Packaging Systems business. Besides her involvement with Germfree’s board, Karen currently holds positions on the Boards of Quanterix Corporation and Sotera Health.

Kerry Ingalls is a pharma veteran who brings experience across manufacturing and operations. He previously served as Chief Operating Officer of Poseida Therapeutics, overseeing corporate strategic planning, operations, and the construction, commissioning, and licensing of the CGT manufacturing plant. Prior to his time at Poseida, Kerry held various leadership positions at Amgen for many years, managing multiple operations sites and overseeing all clinical and commercial GMP manufacturing at Amgen’s global headquarters. Before joining Amgen, Kerry had a distinguished career in the US Navy.

Helga Salling presently holds the position of Vice President, Global Growth & Strategy- Life Sciences at Jacobs. With over twenty years of experience in the Life Sciences sector, Helga brings valuable expertise to the Germfree Board. Before joining Jacobs, Helga served as VP Integrated Projects at IPS, and before that, she held positions at DPS Group and served as COO at Advent Engineering.

“We are excited to welcome Dorothy, Karen, Kerry and Helga to our Board of Directors.  They bring decades of experience, leadership and strategic thinking in key markets that Germfree serves. We are thrilled to be working with them as we aggressively scale the business to meet the needs of our customers, in particular in the cell and gene therapy space,” said Evis Hursever, Managing Director at EW Healthcare Partners and Chair of the Board of Directors.

About Germfree

Germfree has become a globally recognized authority in cutting-edge critical environment equipment, cleanrooms, and laboratories for over six decades. The company has consistently led the way in pioneering cleanroom design and manufacturing, serving the biopharmaceutical, healthcare, and research sectors. Germfree remains resolutely committed to providing innovative solutions that significantly improve patient access to life-changing therapies.

About EW Healthcare Partners

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe.  EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston.  https://ewhealthcare.com/

Media Contact
Lauren Blum, Content Marketing Manager at Germfree
+1 386-265-4300
[email protected]
www.germfree.com

The post Germfree Announces the Appointment of Four Independent Board Members first appeared on EW Healthcare Partners.

Boiron is a French pharmaceutical company focused on natural medicine, founded in 1932 by pharmacists Jean and Henri Boiron. The company is built around homeopathy and has spearheaded the industry’s global development.

Boiron today is the global market leader in homeopathy and a leading global player in natural medicines, with 2022 revenues of €534M. The company offers a diversified portfolio of natural, innovative, science-based, and personalized pharmaceutical products. Over 50% of Boiron’s sales are realized outside of France. Boiron benefits from an integrated value chain from registration to distribution, including in-house manufacturing, with the company currently present in 50 countries globally through 23 subsidiaries and 30 distributors. Boiron has also established a strong footprint in the U.S. with €120M in U.S. revenue, with a large portion of products sold through the e-commerce channel.

EW Healthcare Partners is excited to partner with the Boiron family to help further accelerate the company’s growth, by expanding the company’s offering into additional healthcare verticals and capitalising on the existing platform to launch additional products, in particular in the U.S.

About EW Healthcare Partners (“EW”)

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston. https://www.ewhealthcare.com

The post EW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural Medicine first appeared on EW Healthcare Partners.

SAN JOSE, California—(BUSINESS WIRE)—VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed Series F financing in excess of $30 million. The financing round was led by Revelation Partners with significant participation from the company’s existing investors, including Pacific General Ventures and EW Healthcare Partners. The additional funding will support VitalConnect’s rapidly growing remote cardiac monitoring business while advancing key partnerships with the largest hospital systems in the United States to provide remote patient monitoring in an in-patient setting.

“VitalConnect’s services have been widely adopted at an accelerated pace over the past 24 months, enabling our revenue to triple from 2021 to 2022, and putting us on track to nearly double revenue again in 2023. We are also experiencing significant EBITDA improvement and we expect to achieve profitability in 2024,” said Peter Van Haur, CEO of VitalConnect. “This latest round of financing, at an increased valuation, signals unwavering support from our investors while providing the company the runway needed to achieve our goal of being the world’s leading provider of remote patient monitoring solutions.”

“Revelation Partners is excited to join the distinguished list of VitalConnect investors to help further accelerate the company’s already impressive growth,” said Fred Lee, Partner at Revelation Partners. “VitalConnect is in the unique position of being able to meaningfully participate in multiple billion-dollar markets that are growing at double-digit rates. The adoption of the technology in the marketplace, thus far, has been unprecedented, thereby giving us confidence in the leadership team’s ability to execute. We are committed to supporting the organization to enable them to maximize both revenue and profitability.”

Founded in 2011, VitalConnect has deployed hundreds of thousands of biosensors throughout the world, including leading healthcare facilities such as Brigham and Women’s, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients.

About VitalConnect, Inc.

VitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes. VitalConnect’s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. VitalConnect’s advanced, yet easy-to-use, platform, was designed to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers. For more information: www.vitalconnect.com.

About Revelation Partners

Revelation Partners provides flexible capital solutions to the healthcare ecosystem. These customized solutions provide liquidity, align shareholders, and support the growth of privately-held healthcare companies. The firm’s long-term approach allows it to address the issues faced by a wide range of counterparties, including founders, company management teams, institutional investors (including general partners), and limited partners. For more information: www.revelation-partners.com.

Contacts
Media Contacts:

Steve Kelly
VitalConnect, Inc.
206-856-6488
[email protected]

Fred Lee
Revelation Partners
415-308-3896
[email protected]

The post VitalConnect Secures over $30 Million in Oversubscribed Series F Financing first appeared on EW Healthcare Partners.

Josh Griffith joins Grundium bringing 18+ years of sales and marketing experience in the global diagnostics industry driving capital equipment, consumable, and royalty revenues. Prior to joining Grundium Josh served as Vice President Global Marketing at Luminex – A DiaSorin Company.

Andy Thomson brings more than three decades of commercial and leadership experience to the board of Grundium. As a seasoned executive, Andy has spent significant time across the diagnostics and life sciences space through a career at three large companies. He has served as SVP EMEA and SVP and Group President of specialty Diagnostics at Thermo Fisher. Prior to joining Thermo, he was SVP and General Manager of the Centralised Diagnostics division at Roche. Before joining Roche, Andy was VP of Marketing at Dade Behring. In addition to the board of Grundium, Andy currently serves on the Boards of TubeWriter, ClearStart Inc. and Spectrum Solutions.

Chris Linthwaite is a life sciences veteran who brings experience across tools diagnostics and genomics. He is currently Chief Executive Officer at Scram Systems. Prior to joining Scram, Chris served as CEO of Fluidigm, since 2016. Prior to joining Fluidigm in 2016, Chris served as President of the Genetic Sciences platform at Life Technologies, managing four technology platforms across Genetic, Medical and Applied Sciences Division.

“We are excited to welcome Josh to the Grundium team and Andy and Chris to our board of directors. Josh’s high energy and in-depth knowledge in the IVD and research market will be fundamental in leading our sales and marketing operations in the US to leverage the potential of our unique product and technology portfolio. We have wanted to establish a footprint in the US since we founded Grundium and I’m happy to establish our US operations with Josh at the helm” said Mika Kuisma, Grundium CEO.

“We are thrilled to welcome Josh to the team and are excited to be able to work with Andy and Chris as we aggressively expand the business in the US and in the human digital pathology space. Andy and Chris’ deep expertise in life sciences tools global businesses will be invaluable to our board as we grow the business and expand the operations in particular in the US,” said Evis Hursever, Managing Director at EW Healthcare Partners and Chair of the Board of Directors.

About Grundium Oy

A leader in advanced imaging technology, Grundium makes digital pathology and best professional diagnosis available for all life – whether human, animal, plant or other. This is achieved by applying state-of-the-art mobile technology in digital pathology. Established in 2015 by ex-Nokia engineers, the Tampere-based company is democratizing digital pathology with the Ocus® microscope scanners. The cutting-edge imaging solutions are based on over 20 years of experience in optics, sensors and beautiful high-precision devices. https://www.grundium.com/

About EW Healthcare Partners

With over $4 billion raised since inception, EW Healthcare Partners makes growth equity investments in fast growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. Since its founding in 1985, EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been a long-term investor in over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of senior investment professionals located in their offices in New York, London and Houston. https://ewhealthcare.com/

The post Grundium Oy Announces the Appointment of Head of the US Business and Two Independent Board Members first appeared on EW Healthcare Partners.